NCT06289894View on ClinicalTrials.gov

A Study of BRY805 in Participants With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

September 30, 2027

Conditions
Advanced Solid Tumor
Interventions
DRUG

BRY805 injection

BRY805 will be administered via IV infusion every 3 weeks. , Six dose levels of 0.3, 1, 3, 9,18 and 30 mg/kg will be tested

Trial Locations (1)

250117

Shandong Tumor hospital, Jinan

Sponsors
All Listed Sponsors
lead

BioRay Pharmaceutical Co., Ltd.

INDUSTRY